Markets SVB Leerink ups Travere Therapeutics PT to $37 from $27 SVB Leerink raised its price target for Travere Therapeutics (NASDAQ:TVTX) to $37 from $27 and maintained an “outperform” rating after the company reported interim data from the Phase 3 PROTECT study with sparsentan in... August 16, 2021